ClinicalTrials.gg
CompletedNCT03687931Updated May 24, 2019

A Clinical Study to Assess the Efficacy and Safety of Dexamethasone Suspension for Cataract Surgery

A Phase 1/2 interventional study of Dexamethasone in Inflammation Eye, sponsored by iDrop, Inc.. Completed at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2019-05-24.

Sponsored by iDrop, Inc. · Phase 1/2, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Feb 2019, 7 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Endophthalmitis with a site in United States — 1 open to participants now, 1 under way, 1 of them phase 3. Endophthalmitis · United States.

Started
2018
the only one that year
Phase 1/2
Only one
of the 11
Registered
9th of 11
by date
Lead sponsor
1 of 11
iDrop, Inc.

Among the 11 studies in Endophthalmitis with a site in United States, this one is the only one that started in 2018, is the only one in phase 1/2, and was the 9th registered.

Endophthalmitis

65 studies on the registry are indexed under Endophthalmitis; 9 are open to participants now.

Browse Endophthalmitis studies →

Open to participants now

1 of the 11 studies in Endophthalmitis with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 5 Endophthalmitis studies recruiting now, 4 set no upper age limit and none stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Endophthalmitis with a site in United States, or all of them as a file.
02

Study summary

Patients at least 40 years of age who are undergoing cataract surgery will be randomized to receive treatment with one of two dose levels of dexamethasone ophthalmic suspension eye drops to determine if the drops decrease inflammation inside the eye and are safe after cataract surgery.

03

Conditions studied

  • Inflammation Eye

Browse trials for

04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients at least 40 years of age scheduled for unilateral cataract surgery by phacoemulsification with posterior chamber intraocular lens implantation.

Exclusion criteria

Exclusion Criteria:

  • Patients who have received a periocular injection in the study eye in the 3 months prior to screening.
  • Patients who anticipate requiring treatment with any corticosteroids by any route, except inhalation, during the study.
  • Patients who are known steroid responders
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Arm 1

    Dexamethasone suspension dose level 1

    Drug: Dexamethasone

  • Experimental
    Arm 2

    Dexamethasone suspension dose level 2

    Drug: Dexamethasone

Interventions

06

What researchers measure

Primary outcomes

  1. Anterior Chamber Cell

    Number of cells in the anterior chamber

    Time frame: 30 days

07

Study locations

1 site
  • Arizona Eye Center
    Chandler, Arizona 85224, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Feb 2019, 6 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2018
First posted
Sep 27, 2018
StartActual
Aug 26, 2018
Primary completionActual
Feb 28, 2019
CompletionActual
Feb 28, 2019
Last update
May 24, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 24, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03687931
Lead sponsor
iDrop, Inc.
Responsible party
Sponsor
First posted
Sep 27, 2018
Start date
Aug 26, 2018
Primary completion
Feb 28, 2019
Completion
Feb 28, 2019
Last update
May 24, 2019

Study contacts

William White
study chair · iDrop, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexamethasone

Start the discussion